ArticleMolecular cancer research : MCR2019
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.Journal of cancer research and clinical oncology · 2022Pooled it
- Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.Nature communications · 2025Trial
- Review
- STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2025Article
- Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.Journal of medicinal chemistry · 2025Article
- REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients withFuture oncology (London, England) · 2025Article
- New advances in the treatment of EGFR exon20ins mutant advanced NSCLC.American journal of cancer research · 2025Review
- [EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.International journal of molecular sciences · 2024Review
- EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.Targeted oncology · 2024Article
- Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Frontiers in immunology · 2024Review
- HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Article
- The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.JTO clinical and research reports · 2024Article
- Review
- EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.Lung cancer (Amsterdam, Netherlands) · 2023Article
- The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations.JTO clinical and research reports · 2023Article
- [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Structure-Guided Strategies of Targeted Therapies for Patients withBiomolecules · 2023Review
- Advances in the management of non-small-cell lung cancer harbouringTherapeutic advances in medical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Hibiki Udagawa *Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Shinichi Hasako *Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Akihiro OhashiDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Rumi FujiokaDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Yumi HakozakiDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Mikiko ShibuyaDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Naomi AbeDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Toshiharu KomoriDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Tomonori HarumaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Miki TerasakaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Ryoto FujitaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Akihiro HashimotoDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Kaoru FunabashiDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Hiroyuki YasudaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan.
Kazutaka MiyaderaDiscovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Daniel B CostaDivision of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Susumu S KobayashiDivision of Translational Genomics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan. sukobaya@east.ncc.go.jp.ORCID 0000-0003-2262-4001
Taiho Pharmaceutical (Japan) · JPChiba Cancer Center · JPBeth Israel Deaconess Medical Center · USNational Cancer Center Hospital East · JPKeio University · JP
Funding
Unmet needs for specific subsets of EGFR mutated lung cancerR37CA218707 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI COSTA, DANIEL BOTELHO · 2018 to 2024
$2.8MOvercoming resistance to tyrosine kinase inhibitors in lung cancerR01CA169259 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOBAYASHI, SUSUMU · 2013 to 2018
$1.8MEmergence of drug resistant mutations in lung cancerR21CA178301 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOBAYASHI, SUSUMU · 2015 to 2016
$435kNCI NIH HHS R01 CA169259NCI NIH HHS R21 CA178301NCI NIH HHS R37 CA218707
Abstract
Despite the worldwide approval of three generations of EGFR tyrosine kinase inhibitors (TKI) for advanced non-small cell lung cancers with
Indexed as
AcrylamidesAfatinibAniline CompoundsAntineoplastic AgentsBenzene DerivativesCarcinoma, Non-Small-Cell LungCell Line, TumorErbB ReceptorsErlotinib HydrochlorideExonsHumansIndolesIndolizinesLung NeoplasmsMutationProtein Kinase InhibitorsAcrylamidesAfatinibAniline CompoundsAntineoplastic AgentsBenzene DerivativesEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideHM781-36BIndolesIndolizinesosimertinibProtein Kinase InhibitorsPyrimidinesQuinazolineszipalertinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.